The public PBS listing for nusinersen, sold as Spinraza, shows two numbers that do not match. The dispensed price for one 5 millilitre vial of the intrathecal injection is $104,549.24. The general patient charge on the same line is $25.00. Both figures come from the same Pharmaceutical Benefits Scheme item, 13091B, which marks the drug as authority required and listed under the Section 100 Highly Specialised Drugs program.
Anyone with a Medicare card who has collected a script knows the first number is not what they hand over at the counter. The second is closer, especially since 1 January 2026, when the maximum PBS co-payment for general patients fell to $25 from $31.60, while concessional cardholders continue to pay up to $7.70 until 2030 under a longer freeze. The puzzle is not whether taxpayers subsidise medicines. They plainly do. The puzzle is why the price tag on the vial and the price on the receipt are allowed to diverge by more than four orders of magnitude, and what rulebook makes that normal.
Two numbers on one PBS line
Spinraza treats spinal muscular atrophy, a progressive neuromuscular condition. The PBS restricted the listing to particular SMA types and treatment phases; prescribers must obtain authority before the benefit is supplied. When Health Minister Mark Butler announced an extension of the listing to adult patients from 1 August 2022, he said that without subsidy families would pay well over $300,000 per year for nusinersen treatment, and that about 100 patients per year were expected to benefit from the change. Those are ministerial estimates, not prices printed on every receipt, but they signal why the scheme exists: the uncapped market price and the capped patient charge live on different planets.
The July 2021 Pharmaceutical Benefits Advisory Committee public summary document for the adult listing recorded a published price of $110,000 per maintenance vial. The current online listing shows $104,549.24. Confidential price agreements move the dispensed price over time; the patient charge moves on a different schedule entirely.
What the receipt measures
A sensible guess is that the PBS works like a split bill: you pay a set share, the government pays the rest. If that were literally true, expensive drugs would bankrupt patients unless the share were tiny. In practice the share is tiny for the scheme as a whole, but not because the law calculates a percentage of each drug's cost.
In the financial year ending 30 June 2025, government expenditure on subsidised PBS medicines was $19.1 billion, which the scheme's own statistics describe as 91.7% of total medicine costs. Patient contributions were $1.7 billion, or 8.3%. Those 226 million subsidised prescriptions had an average dispensed price of $91.62, meaning patient payment plus government benefit. For general patients holding a Medicare card but no concession card, the average dispensed price was $286.08, and the government contribution toward each of those scripts averaged $258.65.
Put the national split another way. For every dollar patients paid toward those subsidised medicines in 2024-25, taxpayers paid about $11.05 toward the same pool of scripts. That ratio comes from dividing the 91.7% government share by the 8.3% patient share. It is an average across 949 listed medicines and more than five thousand brands, not a rule printed on your receipt, but it shows how far the co-payment sits from a proportional fee.
Cost-of-living pressure still reaches the counter. The Parliamentary Library's review of the 2024-25 health budget noted that the proportion of people who delayed or did not get prescription medicine because of cost rose from 5.6% in 2021-22 to 7.6% in 2022-23. The flat co-payment is meant to keep that barrier predictable even when the taxpayer cost behind it is not.
The shift shows up in the annual statistics. Government cash expenditure accounted for 88.9% of PBS prescription cost in 2017-18 and 91.7% in 2024-25, with patient contributions falling as a share even as total spending grew. Cheaper co-payments and safety-net changes reduce what households pay directly; they do not cap what the scheme spends on each dispensed vial.
The charge the Act names
The National Health Act 1953 draws a bright line between what the patient may be charged and what the Commonwealth pays the pharmacy. Section 87 limits an approved pharmacist supplying a general benefit prescription to charging the general patient charge amount, less any allowable discount, unless a narrower discounted amount applies. That charge is not derived from the drug's dispensed price. It is a statutory cap defined in Part VII of the Act and adjusted through indexation rules.
The compiled Act defines the general patient charge amount as $30.00 before indexation; section 99G adjusts those figures over time. From 1 January 2023 the general co-payment was cut from $42.50 to $30.00; indexation lifted it to $31.60 in 2024. The PBS expenditure report estimated that lower cap saved general patients $283.4 million in 2023-24 alone. Legislation then froze indexation on 1 January 2025, holding the general charge at $31.60 for that calendar year, while the 2024-25 Budget allocated $318 million to co-payment relief including longer freezes for concessional patients. From 1 January 2026 the general maximum fell to $25 for Medicare cardholders, while the concessional co-payment stays at $7.70 until 2030.
None of those political choices link the charge to Spinraza's dispensed price. They only move the ceiling that section 87 enforces.
There is an entire parallel stream of scripts priced below the cap. PBS statistics separate over-co-payment prescriptions, where the government pays a benefit, from under-co-payment prescriptions, where the dispensed price does not exceed the patient charge and the patient pays the full price of the cheap generic with no government contribution for that supply. The 2020-21 expenditure report counts both streams in its totals, including more than 93.6 million under-co-payment prescriptions that year alongside subsidised scripts. Your $25 receipt therefore measures a legal maximum for subsidised items above the cap, not the price of every PBS line.
Brand premiums and special patient contributions can still add to the capped charge for some brands, but the baseline rule is the statutory figure, not a percentage of the manufacturer's price.
Who pays the rest
When the Commonwealth price for a listed drug exceeds the general patient charge, section 99 governs how much the pharmacy receives from the patient and how the Commonwealth settles the balance through the benefit payment system. The patient pays the capped charge (unless the safety net has already cut it further). The taxpayer pays the gap between that charge and the agreed dispensed price for the vial, ampoule or pack dispensed.
That is why Spinraza item 13091B can pair $104,549.24 with a $25.00 general patient charge on the same row. PBAC recommended the listing; the Department negotiated the price that enters the PBS schedule. Butler's 2022 release quoted the government's commitment to expand listings where PBAC recommends them, calling the medicines remarkable and unaffordable without government support. The listing gate controls whether the gap exists at all; the co-payment law controls how much of the gap the patient sees.
General patients are a minority of subsidised volume but a large slice of high-cost scripts. They received 28.9 million of the 226 million subsidised prescriptions in 2024-25, yet accounted for $7.5 billion of the $19.1 billion government spend. Their average dispensed price is pulled upward by specialised medicines like nusinersen, while their counter fee stayed at $31.60 through 2025 before the 2026 cut.
The PBS website states plainly that although the government manages the price of each listed medicine, the total cost of the PBS remains uncapped. New listings, volume growth and price reviews can all expand the taxpayer total even while the counter price stays flat or falls. Spinraza is an extreme cell in that spreadsheet, not an exception to the arithmetic.
Safety net and the uncapped total
Flat co-payments stack with the safety net. In 2024 the general patient safety net threshold was $1,647.90 in out-of-pocket PBS spending in a calendar year; after that point general patients pay $7.70 per script for the rest of the year. Concessional patients have a lower threshold and can reach zero co-payment. Those thresholds change the receipt while leaving the underlying dispensed price untouched.
Concessional cardholders dominate volume: they received 196.7 million of the 226 million subsidised prescriptions in 2024-25, which is why the $7.70 figure matters as much as the $25 headline for households on pensions or health care cards. Spinraza patients may never hit the safety net on a single vial, but millions of chronic scripts do, every year.
Grattan Institute work on PBS pricing argues that Australians pay too much for many scheme drugs and that savings of over $500 million a year could be made through tougher price disclosure and therapeutic group policies, partly because nobody sets an overall PBS spending cap comparable with some overseas purchasers. That critique targets manufacturer prices and program design, not the equity rationale for a flat patient charge. Even if every listed price fell, the legal structure would still decouple the receipt from the vial price until politicians changed the Act.
The vial goes back in the fridge
Spinraza returns to the cold chain after each intrathecal dose. The patient leaves with a $25 receipt, or less if concessional rates or the safety net apply. The schedule still carries a six-figure dispensed price for the vial the pharmacist logged against authority item 13091B. The co-payment was never designed to track that figure. It was designed to stop the charge at the counter while the Commonwealth absorbs whatever sits above it on listed medicines, one vial at a time, across a scheme whose total bill has no ceiling.
The Albanese Government is committed to expanding the PBS, and will continue to list new medicines, or expand PBS listings, where recommended by the independent Pharmaceutical Benefits Advisory Committee.
The listing decides whether Spinraza enters that bargain. Section 87 decides what you pay when it does. The gap between those two numbers is where most of the money lives.
